Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Arcellx Inc ( (ACLX) ) just unveiled an update.
On December 6, 2025, Arcellx, Inc. announced positive results from its Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma, showing a 96% overall response rate and 74% complete response rate. The data, presented at the 67th American Society of Hematology Annual Meeting, indicate deep and durable responses with a manageable safety profile, positioning anito-cel as a potential category leader in multiple myeloma treatment, with plans for a 2026 commercial launch.
The most recent analyst rating on (ACLX) stock is a Buy with a $105.00 price target. To see the full list of analyst forecasts on Arcellx Inc stock, see the ACLX Stock Forecast page.
Spark’s Take on ACLX Stock
According to Spark, TipRanks’ AI Analyst, ACLX is a Neutral.
Arcellx Inc’s overall stock score reflects significant financial challenges, including persistent losses and declining revenues. The technical analysis indicates a bearish trend with weak momentum. The negative P/E ratio and lack of dividend yield further contribute to a low valuation score. The company needs to address these issues to improve its financial health and stock performance.
To see Spark’s full report on ACLX stock, click here.
More about Arcellx Inc
Arcellx, Inc. is a clinical-stage biotechnology company focused on reimagining cell therapy by developing innovative immunotherapies for cancer and other incurable diseases. The company aims to create safer, more effective, and broadly accessible cell therapies.
Average Trading Volume: 703,067
Technical Sentiment Signal: Sell
Current Market Cap: $4.02B
See more insights into ACLX stock on TipRanks’ Stock Analysis page.